Search
Conivaptan
go.drugbank.com/drugs/DB00872ApprovedIt was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH).
Asparagine
go.drugbank.com/drugs/DB00174ApprovedNutraceuticalWithdrawnIt is biosynthesized from aspartic acid and ammonia by asparagine synthetase. (From Concise Encyclopedia Biochemistry and Molecular Biology, 3rd ed)
Velaglucerase alfa
go.drugbank.com/drugs/DB06720ApprovedVelaglucerase alfa is a gene-activated human recombinant glucocerebrosidase used for the treatment of Type 1 Gaucher disease, caused by a deficiency of the lysosomal enzyme glucocerebrosidase.
Dichlorobenzene
go.drugbank.com/drugs/DB14046ApprovedWithdrawnDichlorobenzene refers to any of, or a mixture of, three isomers consisting of benzene in which two of the hydrogen atoms are replaced by chlorine atoms: ortho-, meta-, and paradichlorobenzene.
Lanolin alcohols
go.drugbank.com/drugs/DB14181ApprovedLanolin alcohols are a complex combination of organic alcohols obtained by the hydrolysis of lanolin.
Tafamidis
go.drugbank.com/drugs/DB11644ApprovedInvestigationalTafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives[A27206] developed by FoldRX.[A189717] Tafamidis is structurally similar to diflusinal.
Duvelisib
go.drugbank.com/drugs/DB11952ApprovedInvestigational[A39025] Duvelisib was developed by Verastem, Inc and FDA approved on September 24, 2018.[L4585]
Lonidamine
go.drugbank.com/drugs/DB06266InvestigationalIn such way LND could impair energy-requiring processes, as recovery from potentially lethal damage, induced by radiation treatment and by some cytotoxic drugs. … Lonidamine (LND) is a drug that interferes with energy metabolism of cancer cells, principally inhibiting aerobic glycolytic activity, by its effect on mitochondrially-bound hexokinase (HK).
Agkistrodon piscivorus antivenin
go.drugbank.com/drugs/DB13894ApprovedApproximately 99% of all venomous snake bites in the United States are caused by Crotalidae, also known as _pit vipers_. … The final purified antivenin product is obtained by mixing other different monospecific snake antivenins and isolating the antivenin of interest through fractionation and chromatography techniques.
Catumaxomab
go.drugbank.com/drugs/DB06607ApprovedWithdrawnCatumaxumab was initially authorized for market by the European Medicines Agency in April 2009 for the treatment of malignant ascites [L1122].